Michael Tran
Foot & Ankle Surgery · Arlington, TXNPI 1285652578
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,831 of the $2,784 with a category attached, or 65.8%. 22 manufacturers reported payments, led by Arthrosurface Incorporated at 44.2% of the total. Reporting peaked in 2019 at $1,389 and has fallen 92.7% since, to $101 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.
Across 80 payments — averaging $34.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrosurface Incorporated$1K
- Amgen$253
- Endo USA, Inc.$194
- Paratek Pharmaceuticals, Inc.$152
- Convatec Inc.$150
- Bone Support Inc.$150
- plus $655 from 16 others
Across 4 payments — averaging $6946.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo Pharmaceuticals Inc.$28K
What the payments were for
- Travel & lodging$93534%
- Food & beverage$1,83166%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrosurface Incorporated | 9 | $1,231 |
| Amgen(2 entities) | 13 | $253 |
| Endo USA, Inc. | 4 | $194 |
| Paratek Pharmaceuticals, Inc. | 8 | $152 |
| Convatec Inc. | 1 | $150 |
| Bone Support Inc. | 1 | $150 |
| Zyla Life Sciences, Inc. | 20 | $144 |
| Smith+Nephew | 7 | $133 |
| Trice Medical, Inc. | 1 | $79 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $51 |
| Orthofix Medical, Inc. | 3 | $38 |
| Vertex | 1 | $35 |
| KCI USA, Inc. | 1 | $32 |
| IBSA Pharma Inc. | 1 | $23 |
| ERMI LLC | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Maruho Medical, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Organogenesis Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Assertio Therapeutics, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,784 in reported general payments places this provider in the 40th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 11 | $164 |
| Terbinafine Hcl | 14 | $135 |
| Mupirocin | 14 | $97 |
| Meloxicam | 23 | $87 |
| Cephalexin | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Arlington
- Donald StewartArlington$61K
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.